As of Jul 26
| +0.06 / +1.73%|
The 6 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 11.75, with a high estimate of 15.00 and a low estimate of 4.00. The median estimate represents a +233.81% increase from the last price of 3.52.
The current consensus among 8 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.